Abstract: The present invention relates to a method for identifying a binding site on an RNA transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living cells wherein the living cells incorporate the photoreactive nucleoside into RNA transcripts during transcription thereby producing modified RNA transcripts; reverse transcribing the RNA of isolated cross-linked segments thereby generating cDNA transcripts with one mutation wherein the photoreactive nucleoside is transcribed to a mismatched deoxynucleoside; amplifying the cDNA transcripts thereby generating amplicons; and analyzing the sequences of the amplicons aligned against the reference sequence so as to identify the binding site, wherein the sequences of each amplicon having a mutation resulting from the introduction of the photoreactive nucleoside is considered to be a valid amplicon comprising at least a portion of a binding site on the RNA transcript.

Abstract: The present invention relates to a method for identifying a binding site on an RNA transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living cells wherein the living cells incorporate the photoreactive nucleoside into RNA transcripts during transcription thereby producing modified RNA transcripts; reverse transcribing the RNA of isolated cross-linked segments thereby generating cDNA transcripts with one mutation wherein the photoreactive nucleoside is transcribed to a mismatched deoxynucleoside; amplifying the cDNA transcripts thereby generating amplicons; and analyzing the sequences of the amplicons aligned against the reference sequence so as to identify the binding site, wherein the sequences of each amplicon having a mutation resulting from the introduction of the photoreactive nucleoside is considered to be a valid amplicon comprising at least a portion of a binding site on the RNA transcript.

Abstract: The invention relates to a pharmaceutical composition and the use thereof, wherein the pharmaceutical composition contains compounds selected from a group of general formulas (5), (6), (7) and (8) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. The pharmaceutical composition is used for treating autoimmune and tumoral diseases and/or for immunosuppresion.

Abstract: The present invention relates to a method for identifying a binding site on an RNA transcript, wherein the binding site binds to one or more binding moieties. The method includes, among other things, introducing a photoreactive nucleoside into living cells wherein the living cells incorporate the photoreactive nucleoside into RNA transcripts during transcription thereby producing modified RNA transcripts; reverse transcribing the RNA of isolated cross-linked segments thereby generating cDNA transcripts with one mutation wherein the photoreactive nucleoside is transcribed to a mismatched deoxynucleoside; amplifying the cDNA transcripts thereby generating amplicons; and analyzing the sequences of the amplicons aligned against the reference sequence so as to identify the binding site, wherein the sequences of each amplicon having a mutation resulting from the introduction of the photoreactive nucleoside is considered to be a valid amplicon comprising at least a portion of a binding site on the RNA transcript.

Abstract: The invention relates to compounds selected from among the group comprising general formulas (1), (2), (3), and/or (4) and/or the enantiomers, diastereomers, and derivatives thereof, and the pharmaceutically acceptable salts thereof for producing a medicament used for therapeutically and/or preventively treating disease and pathological conditions linked to regulation of the insulin and/or insulin-like growth factor (IGF) signalling pathway and/or for chemically inducing longevity.

Abstract: The invention relates to drugs and the use thereof, wherein said drugs contain compounds selected from a group comprising general formulas (1), (2), (3) and (4) and/or enantiomers, diastereomers or the pharmaceutically acceptable salts thereof. Said drugs are used for treating autoimmune and tumoral diseases and/or for immunosuppresion.

Abstract: The present invention relates to heat-transfer concentrates for solar installations, containing a) from 92 to 99% by weight of at least one polyglycol of the formula R—O—(CH2—CH2—O)n—H, in which n is an integer of from 3 to 500 and R is H, a C1- to C4-alkyl group or an aromatic radical having 6 to 12 carbon atoms, b) from 1 to 8% by weight of at least one corrosion inhibitor, with the proviso that its content of ethylene glycol and 1,2-propylene glycol is less than 0.2% by weight.

Abstract: The present invention relates to heat-transfer concentrates for solar installations, containing a) from 92 to 99% by weight of at least one polyglycol of the formula R—O—(CH2—CH2—O)n—H, in which n is an integer of from 3 to 500 and R is H, a C1- to C4-alkyl group or an aromatic radical having 6 to 12 carbon atoms, b) from 1 to 8% by weight of at least one corrosion inhibitor, with the proviso that its content of ethylene glycol and 1,2-propylene glycol is less than 0.2% by weight.

Abstract: The invention relates to coolants or antifreeze concentrates containing: a) from 0.05 to 5% by weight of one or more carbamates of the formula in which X is O or S, R is C1- to C8-alkyl or C6- to C18-aryl, or the ammonium salts thereof, b) from 0.05 to 4% by weight of a tricarboxylic acid and/or of a triazinetriiminocarboxylic acid, c) from 0.05 to 8% by weight of a mono- and/or dicarboxylic acid having 4 to 16 carbon atoms, in the form of their alkali metal or ammonium salts, d) from 0.01 to 2% by weight of a hydrocarbon-triazole or hydrocarbon-thiazole, e) from 0.01 to 2% by weight of a water-soluble alkali metal salt and/or alkaline earth metal salt and f) from 80 to 99% by weight of alkylene glycols, polyglycols or glycerol.

Abstract: The present invention relates to antifreeze concentrates comprising a) from 0.05 to 10% by weight of one or more sulfonated or sulfated polyglycols of the formula R—(O)l-(A-O)m—(CH2)k—SO3X in which A is C2- to C4-alkylene, R is H, C1- to C10-alkyl, C2- to C20-alkenyl or C6- to C18-aryl, X is H, an alkali metal or alkaline earth metal, k is a number from 0 to 10, l is 0 or 1, m is a number from 1 to 200, b) from 0.05 to 5% by weight of one or more carbamates of the formula in which X is O or S, R is C1- to C8-alkyl or C6- to C18-aryl, or a corresponding ammonium salt, c) from 0.05 to 5% by weight of an aliphatic or aromatic amine, d) from 0.01 to 1% by weight of a hydrocarbon-triazole, e) alkylene glycols to 100% by weight.

Abstract: The present invention relates to antifreeze concentrates comprising